Global Next Generation Cancer Diagnostic Devices Market 2012-2016

世界の次世代癌診断(Cancer Diagnostic)デバイス市場(2012-2016)

◆タイトル:Global Next Generation Cancer Diagnostic Devices Market 2012-2016
◆商品コード:IRTNTR1970
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2013年3月7日
◆ページ数:35
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Five UserUSD2,300 ⇒換算¥253,000見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本調査レポートでは、"世界の次世代癌診断(Cancer Diagnostic)デバイス市場(2012-2016)"について調査・分析し、エグゼクティブサマリー、市場概観、市場規模及び予測、主要地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析等の情報をお届けいたします。

TechNavio’s analysts forecast the Global Next-generation Cancer Diagnostic Devices market to grow at a CAGR of 48.11 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of cancer. The Global Next-generation Cancer Diagnostic Devices market has also been witnessing an increase in mergers and acquisitions among vendors. However, intense competition among vendors could pose a challenge to the growth of this market.

TechNavio’s report, Global Next-generation Cancer Diagnostic Devices Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it covers the Global Next-generation Cancer Diagnostic Devices market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this space are Roche Holding Ltd., Abbott Laboratories, Siemens Healthcare, and Agilent Technologies Inc.

The other vendors mentioned in the report are Illumina Inc., Becton Dickinson and Co., QIAGEN N.V., Affymetrix Inc., Johnson & Johnson, Thermo Fisher Scientific Inc., GE Healthcare, Life Technologies Corp., Luminex Corp., Cepheid Inc., bioMerieux SA, Allegro Diagnostics Corp., Fluidigm Corp., Nanosphere Inc., PerkinElmer Inc., Randox Laboratories Ltd., Oncolys BioPharma Inc., SomaLogic Inc., Radient Pharmaceuticals Corp., Quest Diagnostics Inc., Asuragen Inc., AVIVA Biosciences Corp., Veridex LLC, A. Menarini Diagnostics S.r.l., and Fujirebio Diagnostics Inc.

Key questions answered in this report:
What will the market size be in 2016 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of each of these key vendors?

【資料の目次】

01. Executive Summary
02. Introduction
03. Market Coverage
Market Overview
Product Offerings
04. Market Landscape
04.1 Market Size and Forecast
04.2 Market Segmentation
04.3 Five Forces Analysis
05. Geographical Segmentation
06. Vendor Landscape
Major Vendors in the Global In Vitro Diagnostics Market
07. Buying Criteria
08. Market Growth Drivers
09. Drivers and their Impact
10. Market Challenges
11. Impact of Drivers and Challenges
12. Market Trends
13. Key Vendor Analysis
13.1 Roche Holding Ltd.
Business Overview
Key Information
SWOT Analysis
13.2 Abbott Laboratories
Business Overview
Key Information
SWOT Analysis
13.3 Agilent Technologies Inc.
Business Overview
Key Information
SWOT Analysis
13.4 Siemens Healthcare
Business Overview
Key Information
SWOT Analysis
14. Other Reports in this Series
List of Exhibits
Exhibit 1: Global Next-generation Cancer Diagnostic Devices Market 2012-2016 (US$ billion)
Exhibit 2: Global Next-generation Cancer Diagnostic Devices Market Segmentation
Exhibit 3: Global Next-generation Cancer Diagnostic Devices Market Segmentation 2012
Exhibit 4: Global Next-generation Cancer Diagnostic Devices Market by Geographical Segmentation 2012
Exhibit 5: Global In Vitro Diagnostics Market by Vendor Segmentation 2012
Exhibit 6: Business Segmentation of Roche Holding Ltd.
Exhibit 7: Business Segmentation of Abbott Laboratories
Exhibit 8: Business Segmentation of Agilent Technologies Inc.



【掲載企業】

Roche Holding Ltd., Abbott Laboratories, Siemens Healthcare, Agilent Technologies Inc., Illumina Inc., Becton Dickinson and Co., QIAGEN N.V., Affymetrix Inc., Johnson & Johnson, Thermo Fisher Scientific Inc., GE Healthcare, Life Technologies Corp., Luminex Corp., Cepheid Inc., bioMerieux SA, Allegro Diagnostics Corp., Fluidigm Corp., Nanosphere Inc., PerkinElmer Inc., Randox Laboratories Ltd., Oncolys BioPharma Inc., SomaLogic Inc., Radient Pharmaceuticals Corp., Quest Diagnostics Inc., Asuragen Inc., AVIVA Biosciences Corp., Veridex LLC, A. Menarini Diagnostics S.r.l., and Fujirebio Diagnostics Inc.

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[世界の次世代癌診断(Cancer Diagnostic)デバイス市場(2012-2016)] (Global Next Generation Cancer Diagnostic Devices Market 2012-2016 / IRTNTR1970)販売に関する免責事項
[世界の次世代癌診断(Cancer Diagnostic)デバイス市場(2012-2016)] (Global Next Generation Cancer Diagnostic Devices Market 2012-2016 / IRTNTR1970)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆